Clinical trial
Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus…
NCT00426361 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00426361 |
|---|---|
| Title | Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects |
| Official title | A Multicentre Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine (580299) Co-administered With Boostrix Polio (dTpa-IPV) in Healthy Female Subjects Aged 10-18 Years |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Infections, Papillomavirus |
| Intervention type | Biological |
| Interventions | Boostrix ® Polio, GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM) |
| Enrollment | 751 |
| Start date | Feb 13, 2007 |
| Primary completion | Mar 17, 2008 |
| Completion | Jul 25, 2008 |
| First posted | Jan 24, 2007 |
| Last update posted | Jul 20, 2018 |
| Countries | France, Germany, Spain |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: